pharmaceutical investing Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
pharmaceutical investing Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
pharmaceutical investing AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
pharmaceutical investing AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
pharmaceutical investing AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
pharmaceutical investing U.S. FDA Approves DECNUPAZTM for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
pharmaceutical investing AbbVie Announces Positive CHMP Opinion for MAVIRET® for the Treatment of Acute Hepatitis C Infection
pharmaceutical investing AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
pharmaceutical investing Allergan Aesthetics Receives Positive CHMP Opinion for Boey® for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
pharmaceutical investing AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases at 2026 Digestive Disease Week®
pharmaceutical investing SKYRIZI® Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis
pharmaceutical investing AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
